ATE540028T1 - Als hsp90-inhibitoren geeignete triazinon- und diazinonderivate - Google Patents
Als hsp90-inhibitoren geeignete triazinon- und diazinonderivateInfo
- Publication number
- ATE540028T1 ATE540028T1 AT08742209T AT08742209T ATE540028T1 AT E540028 T1 ATE540028 T1 AT E540028T1 AT 08742209 T AT08742209 T AT 08742209T AT 08742209 T AT08742209 T AT 08742209T AT E540028 T1 ATE540028 T1 AT E540028T1
- Authority
- AT
- Austria
- Prior art keywords
- triazinone
- hsp90 inhibitors
- derivatives suitable
- subject
- hsp90
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/10—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92032707P | 2007-03-27 | 2007-03-27 | |
| PCT/US2008/003810 WO2008118391A2 (en) | 2007-03-27 | 2008-03-24 | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540028T1 true ATE540028T1 (de) | 2012-01-15 |
Family
ID=39739347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08742209T ATE540028T1 (de) | 2007-03-27 | 2008-03-24 | Als hsp90-inhibitoren geeignete triazinon- und diazinonderivate |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8524712B2 (de) |
| EP (1) | EP2155694B1 (de) |
| JP (1) | JP5529004B2 (de) |
| AT (1) | ATE540028T1 (de) |
| AU (1) | AU2008232354B9 (de) |
| CA (1) | CA2682665C (de) |
| ES (1) | ES2395114T3 (de) |
| TW (1) | TWI427068B (de) |
| WO (1) | WO2008118391A2 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2586612C (en) | 2004-11-18 | 2016-10-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| CA2618377A1 (en) | 2005-08-12 | 2007-02-22 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate hsp90 activity |
| US20070250391A1 (en) * | 2006-04-05 | 2007-10-25 | Prade Hendrik D | Merchandising system and method for food and non-food items for a meal kit |
| EP2034996A2 (de) | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Hsp90-aktivität modulierende triazolverbindungen |
| TW200800260A (en) | 2006-05-25 | 2008-01-01 | Synta Pharmaceuticals Corp | Method for treating proliferative disorders associated with protooncogene products |
| EP2032545A2 (de) * | 2006-05-25 | 2009-03-11 | Synta Pharmaceuticals Corporation | Verbindungen als modulatoren der hsp90-aktivität und verfahren für ihre identifizierung |
| RS53446B (en) | 2006-05-25 | 2014-12-31 | Synta Pharmaceuticals Corp. | TRIAZOLE UNITS MODULATING HSP90 ACTIVITY |
| EP2026797A2 (de) | 2006-05-25 | 2009-02-25 | Synta Pharmaceuticals Corporation | Verfahren zur behandlung von non-hodgkin-lymphom |
| US9156836B2 (en) * | 2008-05-16 | 2015-10-13 | Synta Pharmaceuticals Corp. | Tricyclic triazole compounds that modulate HSP90 activity |
| WO2009148599A1 (en) | 2008-06-04 | 2009-12-10 | Synta Pharmaceuticals Corp. | Pyrrole compunds that modulate hsp90 activity |
| US8648071B2 (en) | 2008-06-27 | 2014-02-11 | Synta Pharmaceuticals Corp. | Hydrazonamide compounds that modulate Hsp90 activity |
| ES2415234T3 (es) * | 2008-08-08 | 2013-07-24 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad Hsp90 |
| WO2010017545A2 (en) | 2008-08-08 | 2010-02-11 | Synta Pharamceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| BRPI1013999B1 (pt) | 2009-07-10 | 2020-06-02 | Taiho Pharmaceutical Co., Ltd. | Composto de azabiciclo e um sal deste, produto farmacêutico e composição farmacêutica compreendendo dito composto e uso do mesmo para tratar câncer |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| US8741915B2 (en) | 2009-09-25 | 2014-06-03 | N30 Pharmaceuticals, Inc. | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors |
| WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| WO2012039718A1 (en) | 2010-09-24 | 2012-03-29 | N30 Pharmaceuticals, Llc | Novel dihydropyrimidin-2(1h)-one compounds as neurokinin-3 receptor antagonists |
| WO2012087943A2 (en) * | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
| US8906885B2 (en) | 2011-07-07 | 2014-12-09 | Synta Pharmaceuticals Corp. | Treating cancer with HSP90 inhibitory compounds |
| WO2013014170A1 (en) * | 2011-07-27 | 2013-01-31 | Ab Science | Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
| AU2012339679A1 (en) | 2011-11-14 | 2014-06-12 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with BRAF inhibitors |
| EP2877493B1 (de) | 2012-07-25 | 2018-03-21 | Celldex Therapeutics, Inc. | Anti-kit-antikörper und verwendungen davon |
| AU2014228822A1 (en) | 2013-03-15 | 2015-10-01 | Memorial Sloan-Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN106659782B (zh) | 2014-05-23 | 2021-11-09 | 塞尔德克斯医疗公司 | 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体 |
| CN113521314A (zh) | 2014-09-17 | 2021-10-22 | 纪念斯隆-凯特琳癌症中心 | Hsp90-靶向炎症和感染成像及治疗 |
| WO2018049092A1 (en) * | 2016-09-09 | 2018-03-15 | University Of Cincinnati | Small molecule prolactin receptor inhibitors, pharmaceutical compositions and treatment methods using such inhibitors |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| CN109666024A (zh) * | 2018-03-20 | 2019-04-23 | 兰州大学 | 2-氧嘧啶类化合物及其制备方法和用途 |
| CN110105366B (zh) * | 2019-05-29 | 2021-06-01 | 华中农业大学 | 一种喹啉衍生物VCTb9及其在制备抗癌药物中的应用 |
| CN110105365B (zh) * | 2019-05-29 | 2021-08-10 | 华中农业大学 | 一种喹啉衍生物VCTb5及其在制备抗癌药物中的应用 |
| JP2023532298A (ja) * | 2020-07-02 | 2023-07-27 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物及び方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4239540A1 (de) * | 1992-11-25 | 1994-05-26 | Asta Medica Ag | Neue heterocyclische Verbindungen mit antiasthmatischer/antiallergischer, entzündungshemmender, positiv inotroper und blutdrucksenkender Wirkung |
| GB0315111D0 (en) * | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| GB0320300D0 (en) * | 2003-08-29 | 2003-10-01 | Cancer Rec Tech Ltd | Pyrimidothiophene compounds |
| EP1675834A4 (de) * | 2003-10-16 | 2008-08-27 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren |
| WO2005100341A1 (ja) * | 2004-04-15 | 2005-10-27 | Astellas Pharma Inc. | ２－アミノピリミジン誘導体 |
| US7473669B2 (en) * | 2005-05-03 | 2009-01-06 | Dow Agrosciences Llc | Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-triazin-6-ones, and their use as fungicides |
| EP2049497A2 (de) * | 2005-05-19 | 2009-04-22 | Astex Therapeutics Limited | Pyrimidinderivate als hsp90-inhibitoren |
| DE102005022977A1 (de) * | 2005-05-19 | 2006-12-07 | Merck Patent Gmbh | Phenylchinazolinderivate |
-
2008
- 2008-03-24 EP EP08742209A patent/EP2155694B1/de not_active Not-in-force
- 2008-03-24 JP JP2010500949A patent/JP5529004B2/ja not_active Expired - Fee Related
- 2008-03-24 WO PCT/US2008/003810 patent/WO2008118391A2/en active Application Filing
- 2008-03-24 US US12/593,147 patent/US8524712B2/en active Active
- 2008-03-24 CA CA2682665A patent/CA2682665C/en not_active Expired - Fee Related
- 2008-03-24 ES ES08742209T patent/ES2395114T3/es active Active
- 2008-03-24 AU AU2008232354A patent/AU2008232354B9/en not_active Ceased
- 2008-03-24 AT AT08742209T patent/ATE540028T1/de active
- 2008-03-27 TW TW097110954A patent/TWI427068B/zh not_active IP Right Cessation
-
2013
- 2013-08-28 US US14/012,408 patent/US20130345219A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200846329A (en) | 2008-12-01 |
| AU2008232354A1 (en) | 2008-10-02 |
| JP5529004B2 (ja) | 2014-06-25 |
| AU2008232354B9 (en) | 2012-07-26 |
| JP2010522750A (ja) | 2010-07-08 |
| CA2682665A1 (en) | 2008-10-02 |
| TWI427068B (zh) | 2014-02-21 |
| CA2682665C (en) | 2015-07-21 |
| US8524712B2 (en) | 2013-09-03 |
| US20100298331A1 (en) | 2010-11-25 |
| EP2155694B1 (de) | 2012-01-04 |
| US20130345219A1 (en) | 2013-12-26 |
| ES2395114T3 (es) | 2013-02-08 |
| WO2008118391A2 (en) | 2008-10-02 |
| WO2008118391A3 (en) | 2008-12-18 |
| EP2155694A2 (de) | 2010-02-24 |
| AU2008232354B2 (en) | 2012-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE540028T1 (de) | Als hsp90-inhibitoren geeignete triazinon- und diazinonderivate | |
| MX2010001565A (es) | Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90. | |
| MX2009008547A (es) | Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer. | |
| TW200738234A (en) | Triazole compounds that modulate HSP90 activity | |
| MX2012000709A (es) | Inhibidores de pirrolopiridina de cinasas. | |
| WO2007139955A3 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2007139967A3 (en) | Triazole compounds that modulate hsp90 activity | |
| TW200637831A (en) | Triazole compounds that modulate Hsp90 activity | |
| WO2007139968A3 (en) | Triazole compounds that modulate hsp90 activity | |
| EA200970542A1 (ru) | ИНГИБИТОРЫ ДЕЙСТВИЯ Akt | |
| WO2007139960A3 (en) | Compounds that modulate hsp90 activity and methods for identifying same | |
| WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| WO2010017545A3 (en) | Triazole compounds that modulate hsp90 activity | |
| MY153243A (en) | Compound for inhibiting mitotic progression | |
| PH12013500913A1 (en) | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| MX2012000711A (es) | Inhibidores de pirrolopirazina de cinasas. | |
| TW200744586A (en) | Therapeutic compounds | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| GEP20125589B (en) | TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS | |
| MA34064B1 (fr) | Compose heterocyclique | |
| WO2008021038A3 (en) | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | |
| TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| WO2010039668A3 (en) | Inhibitors of cyclin kinase inhibitor p21 | |
| WO2009011910A3 (en) | Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment |